LIP
TXG icon

Liontrust Investment Partners’s 10x Genomics TXG Stock Holding History

Liontrust Investment Partners’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-20,000
Closed -$1.12M – 212
2023
Q4 		$1.12M Sell
20,000
-20,000
-50% -$870K 0.02% 157
2023
Q3 		$1.65M Sell
40,000
-70,000
-64% -$3.64M 0.03% 145
2023
Q2 		$6.14M Buy
+110,000
New +$5.95M 0.09% 124

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Liontrust Investment Partners's TXG Position: Q1 2024 in Review

Liontrust Investment Partners sold out of 10x Genomics (TXG) in Q1 2024, closing a stake of 20,000 shares — an estimated $1.12M sold.

Liontrust Investment Partners first reported a position in TXG in Q2 2023 and held it in 3 quarters. The position peaked at $6.14M in Q2 2023. 290 funds tracked by Wall St. Rank hold TXG as of Q1 2024.

  • Liontrust Investment Partners reported no remaining 10x Genomics position as of Q1 2024 after selling out during the quarter.
  • Liontrust Investment Partners sold 20,000 10x Genomics shares in Q1 2024, an estimated $1.12M.
  • Liontrust Investment Partners first reported a position in 10x Genomics in Q2 2023 and held it in 3 quarters.
  • Liontrust Investment Partners's 10x Genomics position peaked at $6.14M in Q2 2023.
  • 290 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2024.

Based on Liontrust Investment Partners's 13F filing for Q1 2024, filed 10 May 2024.